米力农治疗慢性心力衰竭急性加重期的疗效分析

摘要

Objective To analyze the effect of the observation of the milrinone treatment of chronic heart failure with acute exacerbation of treatment. Methods 290 patients grouped, and a control group, the use of diuretics, nitrates, ACE inhibitors or ARB, Low-doseβ-blocker, dopamine and digitalis drugs to conventional treatment, and the other group for the treatment group, in the control group therapy based on the use of milrinone intravenous injection, and then observed, the general cycle of 2 weeks. Then the patient's heart rate, heart pressure, left ventricular end-diastolic diameter (LVED-d), left ventricular ejection fraction (LVEF) and adverse drug reactions comparative analysis. Results The results of the two groups of patients, after two weeks of treatment, the condition of the heart function have been more significant improvement in patients before and after treatment, a statistically significant difference. The treatment group and the control group compared to the patient's heart rate, increased LVEF and 6-minute walk distance, decreased BNP, and the difference was significant. Conclusion Milrinone in the treatment of acute exacerbation of chronic heart failure exacerbation of a significant effect, safe and reliable, it is worth to promote clinical.%　　目的观察分析米力农治疗慢性心力衰竭急性发作期的治疗效果。方法将290例患者进行分组，一组为对照组，使用利尿剂、硝酸酯类、ACEI或ARB、小剂量β受体阻滞剂、多巴胺和洋地黄等药物来进行常规治疗，另一组为治疗组，在对照组治疗的基础之上使用米力农进行静脉注射，然后进行观察，一般周期为2周。然后对患者的心率(HR)、左室舒张末期内径(LVED-d)、左室射血分数(LVEF)、B型脑利钠肽(BNP)、6min步行试验(6MWT)以及使用药物的不良反应情况进行了对比分析。结果两组患者在经过2周的治疗之后，其心功能的状况都得到了较为明显改善。治疗组和对照组相比较患者的心率减慢、LVEF升高、BNP降低，统计学差异具有显著性。结论米力农治疗慢性心力衰竭急性发作加重期的疗效显著且安全可靠，值得在临床上进行推广。